Day: March 28, 2024

Universal Stainless Reports Record Sales; Full Year 2023 Net Income Highest Since 2018

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Record Q4 2023 Sales of $79.8 million, up 12% from Q3 2023; Record full year 2023 sales of $285.9 million, up 42% from 2022 Record Q4 2023 Premium Alloy sales of $21.1 million, up 28% from Q3 2023; Record full year Premium Alloy sales of $68.1 million, up 74% from 2022 Q4 2023 Gross margin improves to 16.4% of sales, highest since Q2 2018, despite $1.6 million raw material headwind Q4 2023 Net Income up 35% from Q3 2023 to $2.6 million, or $0.27 per diluted share Cash flow from operations totals $7.4 million for the quarter; $25.2 million for full year 2023BRIDGEVILLE, Pa., March 28, 2024 (GLOBE NEWSWIRE) — Universal Stainless & Alloy Products, Inc. (Nasdaq: USAP) today reported financial results for the fourth quarter and the full year of 2023. Net sales were up 12% to a record $79.8 million in the 2023 fourth quarter...

Atour Lifestyle Holdings Limited Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

A total of 1,210 hotels or 137,921 hotel rooms in operation as of December 31, 2023. Net revenues for the fourth quarter of 2023 increased by 140.4% year-over-year to RMB1,505 million (US$212 million), compared with RMB626 million for the same period of 2022. Net revenues for full year 2023 increased by 106.2% year-over-year to RMB4,666 million (US$657 million), compared with RMB2,263 million for full year 2022. Net income for the fourth quarter of 2023 was RMB220 million (US$31 million), compared with net loss of RMB83 million for the same period of 2022. Net income for full year 2023 increased by 669.2% year-over-year to RMB739 million (US$104 million), compared with RMB96 million for full year 2022. Adjusted net income (non-GAAP)1 for the fourth quarter of 2023 increased by 175.8% year-over-year to RMB222 million (US$31 million),...

American Oncology Network, Inc. (“AON”) Announces Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Fiscal Year 2023 Revenue was $1,279.2 million, an 11.3% increase over 2022Patient encounter growth of 7.9% as compared to the prior fiscal yearFourth Quarter 2023 Revenue was $324.2 million, a 7.9% increase over 2022Patient encounter growth of 9.5% as compared to the prior year quarterFORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) — March 28, 2024 – American Oncology Network, Inc. (NASDAQ: AONC), a leading oncology platform with an innovative model of physician-led, community-based oncology management, today announced financial results for the three- and twelve-month periods ended December 31, 2023. Todd Schonherz, AON chief executive officer, commented, “As a leadership team, we are very proud of our growth and accomplishments in 2023. The organization experienced impressive growth across all aspects of our business...

VEON Pays Back Outstanding Balance and Cancels its Revolving Credit Facility

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Amsterdam, 28 March 2024 – VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services (the “Company”), announces that it has repaid in full the outstanding balance of USD 805 million (principal, excluding accrued interest) under its revolving credit facility (“RCF”) and cancelled the RCF. The repayment of the outstanding amount and the cancellation of the RCF will reduce VEON’s interest expenses, in line with our effective cash and balance sheet management practices. Important NoticeElements of this press release contain or may contain “inside information” as defined under the Market Abuse Regulation (EU) No. 596/2014. About VEON VEON is a digital operator that provides converged connectivity and digital services to nearly 160 million customers. Operating across...

PunaMusta Media on toteuttanut medialiiketoiminnan kaupan Keskisuomalaiselle

Written by Customer Service on March 28, 2024. Posted in Public Companies.

PUNAMUSTA MEDIA OYJ PÖRSSITIEDOTE 28.3.2024 KLO 10.00 PunaMusta Media Oyj on tänään 28.3.2024 toteuttanut tytäryhtiöidensä Sanomalehti Karjalainen Oy:n, Karelia Viestintä Oy:n ja PunaMusta Paikallismediat Oy:n koko osakekantojen myynnin Keskisuomalainen Oyj:lle. Medialiiketoiminta siirtyy Keskisuomalaisen omistukseen 1.4.2024. Samalla PunaMusta Media-konserni luopuu medialiiketoiminnastaan. PunaMusta Media Oyj tiedotti 31.1.2024 allekirjoittaneensa kauppakirjan medialiiketoiminnan myynnistä Keskisuomalainen Oyj:lle. Kaupan täytäntöönpano oli ehdollinen Kilpailu- ja kuluttajaviraston hyväksynnälle. Kilpailu- ja kuluttajavirasto ilmoitti hyväksyneensä kaupan 6.3.2024. Osakekauppojen velaton kauppahinta on 8,5 miljoonaa euroa, joka maksettiin kaupan toteuttamishetkellä. PunaMusta Media kirjaa konsernissa arvioidun myyntivoiton noin 10,2...

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

Written by Customer Service on March 28, 2024. Posted in Public Companies.

DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) — Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years, building a strong balance sheet, commercialising the innovative melanocortin drug SCENESSE®, and plans to bring melanocortin technology to wider audiences with unmet needs. CLINUVEL is now investing heavily in R&D with an ambitious clinical pipeline, including a phase III clinical trial for the pigment loss disorder vitiligo. A case...

Correction: Amber Grid Investor’s Calendar for 2024

Written by Customer Service on March 28, 2024. Posted in Public Companies.

AB Amber Grid, legal entity code: 303090867. Address: Laisvės ave. 10, LT-04215 Vilnius, Lithuania. Amber Grid is changing the investor calendar published for 2024 as follows: • 30.04.2024 – resolutions of the Annual General Meeting of Shareholders;• 10.05.2024 – interim information for the three months of 2024;• 09.08.2024 – interim information for the six months of 2024;• 08.11.2024 – interim information for the nine months of 2024. More information: Laura Šebekienė, Head of Communications of Amber Grid,Tel. +370 699 61 246, e-mail: l.sebekiene@ambergrid.lt

Caledonia Mining Corporation Plc Results for the Year ended December 31, 2023; Notice of Management Conference Call; Dividend Declaration

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

ST HELIER, Jersey, March 28, 2024 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) announces its operating and financial results for the year ended December 31, 2023 (the “Year”). Further information on the financial and operating results for the Year and the quarter ended December 31, 2023 (the “Quarter” or “Q4”) can be found in the Management Discussion and Analysis (“MD&A”), and the audited financial statements, which are available on the Company’s website and which are being filed on SEDAR. Following the trading update of March 4, 2024, the Company is trading in line with both market expectations and production guidance for 2024. The Company also declares a quarterly...

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Significant corporate and scientific progress in 2023 Innovations to End-to-End Platform technologies and IP portfolio Pipeline additions with multiple KRAS neoantigen targets Advancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with new scientific partnership with the National Cancer Institute and further collaboration for new costimulatory switch protein with Helmholtz Munich Updates to strategy going forward to develop both TCR-T therapies and additional, non-autologous, TCR-based modalities leveraging Medigene’s best-in-class TCR generation capabilities Cash runway extended into April 2025 Company to host a conference call today, March 28, 2024, at 3 pm CET/ 10 am ETPlanegg/Martinsried, March 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology...

Renault Group sold to Nissan 99,132,100 Nissan shares for €358 million

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Press Release March 28, 2024 Renault Group sold to Nissan 99,132,100 Nissan shares for €358 million Boulogne-Billancourt, March 28, 2024 After a first sale of Nissan shares on December 13, 2023, Renault Group has completed a second transaction on March 28, 2024 and sold to Nissan 99,132,100 Nissan shares, representing approximately 2.5% of Nissan’s capital. It results in a cash inflow of €358 million, which improves the Automotive net cash financial position and allows faster deleveraging of the Group. It also supports the Group’s target to return to an investment grade rating. This sale results from the exercise by Nissan of its right of first offer to acquire 99,132,100 Nissan shares following a notice from Renault Group expressing its intention to sell 280,690,000 Nissan shares (representing up to 7% of Nissan capital)....

Day: March 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice